Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
November 13, 2024 07:30 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 30, 2024 06:14 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
October 22, 2024 07:30 ET
|
Lexeo Therapeutics
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
September 05, 2024 07:30 ET
|
Lexeo Therapeutics
Lexeo Therapeutics to Participate in Upcoming Investor Conferences - September 2024
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
August 12, 2024 07:00 ET
|
Lexeo Therapeutics
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and...
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
July 15, 2024 06:00 ET
|
Lexeo Therapeutics
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months...
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
July 11, 2024 08:00 ET
|
Lexeo Therapeutics
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
July 08, 2024 07:00 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024 07:00 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
May 07, 2024 07:30 ET
|
Lexeo Therapeutics
Lexeo Therapeutics to Participate in Upcoming Investor Conferences